Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK) on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily furnished on Form 20-F and Form 6-K as a foreign private issuer. Takeda prepares its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) and uses these filings to report semi-annual and annual results, management guidance and material developments in its business.
Recent Form 6-K submissions include English translations of Takeda’s semi-annual securities report and earnings report (Kessan Tanshin) for the six-month period ended September 30, 2025. These documents present revenue by business area (Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, Neuroscience and Other) and by geographic region, along with operating profit, net profit, cash flow information and explanations of non-IFRS core measures such as core revenue, core operating profit and core EPS. They also discuss factors affecting performance, including generic erosion of specific products, foreign exchange impacts and changes in product mix.
Takeda’s 6-K filings additionally furnish press releases that describe key R&D and strategic events, such as Phase 3 data for zasocitinib (TAK-279) in plaque psoriasis, longer-term VERIFY and THRIVE results for rusfertide in polycythemia vera, portfolio decisions like discontinuation of cell therapy efforts, and revised forecasts for FY2025 revenue and profit. These exhibits provide context on how clinical outcomes, impairments of intangible assets and strategic partnerships influence Takeda’s financial outlook.
Through Stock Titan, users can review Takeda’s SEC filings as they are posted, while AI-powered tools can help summarize lengthy IFRS financial reports, highlight changes in management guidance, and surface important disclosures related to pipeline programs, impairments, capital allocation and regional performance. This makes it easier to understand how Takeda’s global biopharmaceutical operations and late-stage pipeline are reflected in its official U.S. regulatory documents.
Takeda Pharmaceutical Company Limited reported mixed results for the nine months ended December 31, 2025. Revenue fell to JPY 3,411.2 billion, down 3.3% year over year, mainly because its ADHD drug VYVANSE in the U.S. faced heavy generic competition, sharply reducing Neuroscience revenue.
Despite lower sales, cost controls and fewer restructuring charges helped operating profit edge up 1.2% to JPY 422.4 billion, while net profit rose 2.4% to JPY 216.3 billion. Core operating profit and Core EPS declined about 3–4% as Takeda absorbed lower Neuroscience revenue and higher impairments on certain R&D assets.
The balance sheet strengthened, with total assets at JPY 15.4 trillion and the equity ratio improving to 49.6%. Operating cash flow increased to JPY 966.9 billion, supporting ongoing dividends; the company projects a full-year dividend of JPY 200 per share. Management slightly raised FY2025 revenue, operating profit and EPS forecasts, mainly from foreign-exchange tailwinds, but revised Core Revenue guidance to a low-single-digit decline at constant exchange rates.
Takeda reported strong Phase 3 results for its investigational oral psoriasis drug zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis. Two large, randomized, double-blind studies showed zasocitinib was superior to placebo at week 16 on both co-primary goals: static Physician Global Assessment (sPGA 0/1) and Psoriasis Area and Severity Index (PASI 75). All 44 ranked secondary endpoints, including higher bars of PASI 90 and PASI 100 against both placebo and apremilast, were also met.
More than half of treated patients achieved clear or almost clear skin (PASI 90), and on average about 30 percent reached completely clear skin (PASI 100) by week 16, with responses continuing to improve through week 24. Zasocitinib was generally well-tolerated, with common side effects such as upper respiratory infections, nasopharyngitis and acne, and no new safety signals. Takeda plans to submit a New Drug Application to the U.S. Food and Drug Administration and other regulators starting in fiscal year 2026, and currently expects these results to have no significant impact on its full-year forecast for the fiscal year ending March 31, 2026.
Takeda Pharmaceutical Company Limited shareholder plans to sell American Depositary Shares under Rule 144. The notice covers the proposed sale of 29,619 ADSs through Interactive Brokers LLC on the NYSE, with an aggregate market value of $421,182.18. The filing states that 123,490,548 ADSs were outstanding at the time of the notice. The ADSs to be sold were acquired as vested restricted stock unit awards from Takeda on three dates, with 20,046 ADSs acquired on July 1, 2023, 13,592 ADSs on July 1, 2022, and 5,858 ADSs on July 1, 2021, each described as compensation.
Takeda Pharmaceutical Company Limited filed a Form 6-K highlighting new longer-term clinical data for rusfertide, a Phase 3 investigational treatment for polycythemia vera developed with Protagonist Therapeutics. At 52 weeks in the pivotal VERIFY study, 61.9% of patients continuously treated with rusfertide plus standard care maintained a durable clinical response, defined by absence of phlebotomy eligibility, and mean hematocrit stayed below 43%, supporting sustained blood count control. Patients who switched from placebo to rusfertide at Week 32 also showed strong responses, with 77.9% achieving absence of phlebotomy eligibility between Weeks 40 and 52. Long-term THRIVE extension data in 46 patients showed a more than 13-fold reduction in annual therapeutic phlebotomy rate, from 9.2 to 0.7 phlebotomies per year, with a safety profile generally consistent with earlier studies and no new signals. Takeda states that the impact of these study results on its financial performance for the fiscal year ending March 31, 2026 is immaterial.
Takeda Pharmaceutical Company Limited has an affiliated holder filing a notice to sell American Depositary Shares (ADSs) under Rule 144. The planned sale covers 87,023 ADSs with an aggregate market value of $1,242,688.44, to be executed through Interactive Brokers LLC on the NYSE, with an approximate sale date of 12/05/2025. The table notes that 123,490,548 ADSs are outstanding.
The securities to be sold were acquired as compensation through vested restricted stock unit (RSU) awards from Takeda on three dates: 99,692 ADSs on 07/01/2023, 31,896 ADSs on 07/01/2022, and 17,200 ADSs on 07/01/2021. By signing the notice, the selling person represents that they are not aware of any material adverse, nonpublic information about Takeda’s current or prospective operations.
Takeda Pharmaceutical Company Limited (TAK) insider has filed a notice to sell American Depositary Shares. The filing covers the planned sale of 58,421 ADSs through Interactive Brokers LLC on the NYSE, with an indicated aggregate market value of $836,004.51. The filing notes that 123,490,548 ADSs were outstanding at the time of the notice, providing context for the size of the intended sale.
The seller previously acquired 81,862 ADSs on 07/01/2023 through vested restricted stock unit awards from Takeda Pharmaceutical Company Limited, characterized as compensation. The individual also represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Takeda Pharmaceutical Company (TAK) reported softer first-half FY2025 results as generics and currency weighed on performance. Revenue was JPY 2,219.5 billion (down 6.9% AER), led by a steep decline in Neuroscience from U.S. generic erosion of VYVANSE. Operating profit fell to JPY 253.6 billion (down 27.7%), and net profit to JPY 112.5 billion (down 39.9%). Core metrics were more resilient: core operating profit was JPY 639.2 billion (down 11.2%) and core EPS JPY 279.
ENTYVIO, TAKHZYRO, LIVTENCITY, ADCETRIS and FRUZAQLA helped offset U.S. pressure and FX in GI, Rare Diseases, PDT and Oncology. The company recorded JPY 336.8 billion in amortization and impairment on product intangibles, including JPY 58.2 billion tied to discontinuing a gamma delta T‑cell therapy program. Cash generation remained strong with JPY 593.7 billion from operating activities; cash ended at JPY 681.5 billion. Total equity was JPY 7,131.7 billion and bonds and loans totaled JPY 4,645.3 billion. R&D advanced with positive Phase 3 results for oveporexton in narcolepsy and a collaboration with Innovent in late‑stage oncology.
Takeda Pharmaceutical Company Limited reported six-month results to September 30, 2025 showing lower earnings amid U.S. generic pressure and FX headwinds. Revenue was JPY 2,219.5 billion (-6.9%), operating profit JPY 253.6 billion (-27.7%), and net profit JPY 112.5 billion (-39.9%). Core operating profit was JPY 639.2 billion (-11.2%) with Core EPS of JPY 279.
Performance reflected continued generic erosion of VYVANSE in the U.S., partly offset by growth in ENTYVIO, LIVTENCITY, and TAKHZYRO. Intangible-related charges rose to JPY 336.8 billion, including JPY 58.2 billion tied to discontinuing a gamma delta T‑cell therapy platform. Operating cash flow strengthened to JPY 593.7 billion.
The company revised FY2025 guidance: revenue JPY 4,500.0 billion, operating profit JPY 400.0 billion, net profit JPY 153.0 billion, and EPS JPY 97.14. Core operating profit is JPY 1,130.0 billion and Core EPS JPY 479; management now expects core operating profit and Core EPS to decline by a low single-digit percentage at CER. An interim dividend of JPY 100 per share is set for payment from December 1, 2025, maintaining the annual projection of JPY 200.
FAQ
What is the current stock price of Takeda Pharm (TAK)?
What is the market cap of Takeda Pharm (TAK)?
